Roger Jeffs, Former Co-CEO of United Therapeutics, Joins Pluristem's Strategic Advisory Board
March 26 2018 - 7:00AM
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading
developer of placenta-based cell therapy products, announced today
that Dr. Roger Jeffs has joined Pluristem’s strategic
advisory board. Dr. Jeffs, a highly accomplished biopharma
executive, will advise Pluristem on clinical and commercial
strategies for the Company’s cell therapy programs.
Dr. Jeffs joined United Therapeutics Corporation
during its start-up phase in 1998 as director of research,
development, and medical and led the company as its President and
CEO from 2001 to 2014 and President & co-CEO from 2015 to 2016.
During his successful 18-year tenure at United Therapeutics, Dr.
Jeffs helped lead the company’s initial public offering, oversaw
the clinical development and regulatory approval of six products,
and managed the commercial effort that lead to a significant
increase in revenues. Prior to his time at United Therapeutics, Dr.
Jeffs was previously at Amgen Inc. where he helped lead the
clinical program for Neupogen. Dr. Jeffs holds an
undergraduate degree in chemistry from Duke University and a Ph.D.
in pharmacology from the University of North Carolina School of
Medicine. He served on the Board of Directors for United
Therapeutics from 2001 to 2016, and currently serves on the Boards
of five public companies. Dr. Jeffs is also the co-founder and
co-owner of Bull City Select Investments.
Dr. Jeffs commented, “Pluristem’s placental cell
therapies, currently being evaluated in multiple advanced clinical
trials, could significantly advance regenerative medicine and make
a change in the way patients are treated today, by delivering a
safe and effective off-the-shelf cell therapy. The Company’s
manufacturing assets are a key to its commercialization
capabilities. I look forward to working with Pluristem’s management
team to move the clinical programs forward towards
marketing.”
“Dr. Jeffs brings tremendous expertise and
vision to Pluristem, from business aspects, to clinical
development, marketing approval and commercialization. His work in
developing Neupogen is directly relevant to our PLX-R18 clinical
program in the treatment of bone marrow deficiencies,” stated
Pluristem Chairman and Co-CEO Zami Aberman. “Pluristem is now
forming a senior strategic advisory board in t preparing the
Company toward expansion and commercialization. We are honored and
pleased that Dr. Jeffs is joining us at this important time.”
About Pluristem
Therapeutics
Pluristem Therapeutics Inc. is a leading
developer of placenta-based cell therapy products. The Company has
reported robust clinical trial data in multiple indications for its
patented PLX cells and is entering late-stage trials in several
indications. Our PLX cell products release a range of therapeutic
proteins in response to inflammation, ischemia, muscle trauma,
hematological disorders, and radiation damage. The cells are grown
using the Company's proprietary three-dimensional expansion
technology and can be administered to patients off-the-shelf,
without tissue matching. Pluristem has a strong intellectual
property position; Company-owned and operated, GMP-certified
manufacturing and research facilities; strategic relationships with
major research institutions; and a seasoned management team.
Safe Harbor Statement
This press release contains express or implied
forward-looking statements within the Private Securities Litigation
Reform Act of 1995 and other U.S. Federal securities laws. For
example, Pluristem is using forward-looking statements when it
discusses Pluristem’s clinical trials, that its placental cell
therapies could significantly advance regenerative medicine and
make a change in the way patients are treated, and when it
discusses the potential safety and effectiveness of Pluristem’s
cell therapy and potential expansion and commercialization. These
forward-looking statements and their implications are based on the
current expectations of the management of Pluristem only, and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. The following factors, among others,
could cause actual results to differ materially from those
described in the forward-looking statements: changes in technology
and market requirements; Pluristem may encounter delays or
obstacles in launching and/or successfully completing its clinical
trials; Pluristem’s products may not be approved by regulatory
agencies, Pluristem’s technology may not be validated as it
progresses further and its methods may not be accepted by the
scientific community; Pluristem may be unable to retain or attract
key employees whose knowledge is essential to the development of
its products; unforeseen scientific difficulties may develop with
Pluristem’s process; Pluristem’s products may wind up being more
expensive than it anticipates; results in the laboratory may not
translate to equally good results in real clinical settings;
results of preclinical studies may not correlate with the results
of human clinical trials; Pluristem’s patents may not be
sufficient; Pluristem’s products may harm recipients; changes in
legislation may adversely impact Pluristem; inability to timely
develop and introduce new technologies, products and applications;
loss of market share and pressure on pricing resulting from
competition, which could cause the actual results or performance of
Pluristem to differ materially from those contemplated in such
forward-looking statements. Except as otherwise required by law,
Pluristem undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. For a more detailed description of the risks
and uncertainties affecting Pluristem, reference is made to
Pluristem's reports filed from time to time with the Securities and
Exchange Commission.
Contact:
Karine Kleinhaus, MD, MPH
Divisional VP, North America
1-914-512-4109
karinek@pluristem.com
Efrat Kaduri
Head of Investor and Public Relations
972-74-7108600
efratk@pluristem.com
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Apr 2023 to Apr 2024